FR13C0009I2 - Peptide de suppression de l'appetit, ses compositions et son utilisation - Google Patents

Peptide de suppression de l'appetit, ses compositions et son utilisation

Info

Publication number
FR13C0009I2
FR13C0009I2 FR13C0009C FR13C0009C FR13C0009I2 FR 13C0009 I2 FR13C0009 I2 FR 13C0009I2 FR 13C0009 C FR13C0009 C FR 13C0009C FR 13C0009 C FR13C0009 C FR 13C0009C FR 13C0009 I2 FR13C0009 I2 FR 13C0009I2
Authority
FR
France
Prior art keywords
peptide
compositions
appetite suppression
appetite
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0009C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR13C0009I1 publication Critical patent/FR13C0009I1/fr
Application granted granted Critical
Publication of FR13C0009I2 publication Critical patent/FR13C0009I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0009C 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation Active FR13C0009I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
EP01122701A EP1231218B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use
EP97905000A EP0891378B1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (2)

Publication Number Publication Date
FR13C0009I1 FR13C0009I1 (cg-RX-API-DMAC7.html) 2013-03-22
FR13C0009I2 true FR13C0009I2 (fr) 2013-08-16

Family

ID=26063575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0009C Active FR13C0009I2 (fr) 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation

Country Status (22)

Country Link
EP (4) EP1231218B1 (cg-RX-API-DMAC7.html)
JP (1) JP4064460B2 (cg-RX-API-DMAC7.html)
KR (1) KR100611130B1 (cg-RX-API-DMAC7.html)
CN (1) CN1112367C (cg-RX-API-DMAC7.html)
AT (3) ATE227737T1 (cg-RX-API-DMAC7.html)
AU (1) AU710818B2 (cg-RX-API-DMAC7.html)
BR (1) BR9707807A (cg-RX-API-DMAC7.html)
CA (1) CA2246733C (cg-RX-API-DMAC7.html)
CY (2) CY2619B2 (cg-RX-API-DMAC7.html)
CZ (1) CZ297338B6 (cg-RX-API-DMAC7.html)
DE (3) DE69740176D1 (cg-RX-API-DMAC7.html)
DK (2) DK1975177T3 (cg-RX-API-DMAC7.html)
ES (3) ES2187756T3 (cg-RX-API-DMAC7.html)
FR (1) FR13C0009I2 (cg-RX-API-DMAC7.html)
HU (1) HU229234B1 (cg-RX-API-DMAC7.html)
IL (1) IL125805A0 (cg-RX-API-DMAC7.html)
NO (2) NO323043B1 (cg-RX-API-DMAC7.html)
PL (1) PL187095B1 (cg-RX-API-DMAC7.html)
PT (1) PT1975177E (cg-RX-API-DMAC7.html)
RU (1) RU2197261C2 (cg-RX-API-DMAC7.html)
UA (1) UA70283C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997031943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
PT1975177E (pt) * 1996-03-01 2011-07-26 Novo Nordisk As Peptídeo supressor do apetite, sua composição e uso
BRPI9708566B8 (pt) 1996-04-12 2022-01-18 Ontario Inc 1149336 análogo de glp-2 de mamífero, e, composição farmacêutica.
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) * 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1012188B1 (de) * 1997-09-12 2004-08-18 Pharis Biotec GmbH Zusammensetzung zur therapie von diabetes mellitus und fettsucht
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
ES2310192T3 (es) * 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004069314A1 (en) 2003-02-04 2004-08-19 Novo Nordisk A/S Injection device with rotatable dose setting
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2295452A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
BRPI0718566A2 (pt) 2006-11-08 2014-03-11 Zealand Pharma As Peptídeo, análogo do mesmo, composição farmacêutica, usos de um análogo de peptídeo, e de uma molécula de ácido nucléico, de um vetor de expressão, ou de uma célula hospedeira, molécula de ácido nucléico, vetor de expressão, célula hospedeira, métodos para produzir o análogo de peptídeo-2 tipo-glucagon (glp-2), e, kit terapêutico.
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CN101854947A (zh) * 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
HRP20171801T1 (hr) 2009-09-28 2017-12-29 Intarcia Therapeutics, Inc. Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
DK3551651T3 (da) 2016-12-09 2024-05-13 Zealand Pharma As Acylerede glp-1/glp-2-dobbeltagonister
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
ES2989204T3 (es) 2017-06-16 2024-11-25 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
EP3966224A4 (en) * 2019-05-06 2023-08-23 The University of Sydney PROTEIN FRACTIONATION METHODS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
WO1987002670A1 (en) 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
EP0374165B1 (en) 1987-07-24 1998-09-02 Chiron Corporation Airlift insect cell culture
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
PT1975177E (pt) * 1996-03-01 2011-07-26 Novo Nordisk As Peptídeo supressor do apetite, sua composição e uso

Also Published As

Publication number Publication date
CZ297338B6 (cs) 2006-11-15
DE69717092T2 (de) 2003-07-24
CN1112367C (zh) 2003-06-25
ES2187756T3 (es) 2003-06-16
ATE395359T1 (de) 2008-05-15
EP2295453A2 (en) 2011-03-16
PT1975177E (pt) 2011-07-26
EP1231218B1 (en) 2008-05-14
JP2000505460A (ja) 2000-05-09
JP4064460B2 (ja) 2008-03-19
NO2013006I1 (no) 2013-04-02
KR100611130B1 (ko) 2006-11-30
EP0891378B1 (en) 2002-11-13
CZ273698A3 (cs) 1998-12-16
DE69738695D1 (de) 2008-06-26
EP1975177B1 (en) 2011-04-13
NO323043B1 (no) 2006-12-27
NO2013006I2 (cg-RX-API-DMAC7.html) 2013-03-12
NO984005L (no) 1998-08-31
EP2295453A3 (en) 2011-03-30
EP1975177A1 (en) 2008-10-01
HU229234B1 (en) 2013-09-30
CA2246733A1 (en) 1997-09-04
DK0891378T3 (da) 2003-01-06
PL328732A1 (en) 1999-02-15
CY2619B2 (cg-RX-API-DMAC7.html) 2013-03-13
CN1215405A (zh) 1999-04-28
DE69740176D1 (de) 2011-05-26
EP0891378A1 (en) 1999-01-20
DK1975177T3 (da) 2011-07-25
AU1871597A (en) 1997-09-16
PL187095B1 (pl) 2004-05-31
IL125805A0 (en) 1999-04-11
BR9707807A (pt) 1999-07-27
AU710818B2 (en) 1999-09-30
RU2197261C2 (ru) 2003-01-27
WO1997031943A1 (en) 1997-09-04
EP1231218A2 (en) 2002-08-14
CY2013008I1 (el) 2015-08-05
CA2246733C (en) 2010-07-20
NO984005D0 (no) 1998-08-31
ATE227737T1 (de) 2002-11-15
UA70283C2 (en) 2004-10-15
DE69717092D1 (de) 2002-12-19
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
ES2306685T3 (es) 2008-11-16
ES2364705T3 (es) 2011-09-12
CY2013008I2 (el) 2015-08-05
KR19990087439A (ko) 1999-12-27
FR13C0009I1 (cg-RX-API-DMAC7.html) 2013-03-22
HUP9902670A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
FR13C0009I2 (fr) Peptide de suppression de l'appetit, ses compositions et son utilisation
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
DE69737916D1 (de) Verwendung von GLP-1 Peptiden
DK0966297T4 (da) Regulering af gastrointestinal motilitet
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
ATE303438T1 (de) Menschlicher cysteinyl leukotrien rezeptor 2 (cyslt2)
ATE305478T1 (de) Topoisomerase-ii inhibitoren
GB9614191D0 (en) Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity
MX9601655A (es) Proteinas (ob) obesas recombinantes.